Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Nasdaq

If You Invested $1000 In Marathon Digital Holdings 5 Years Ago, Here's How Much You Would Have Today

Marathon Digital Holdings (NASDAQ:MARA) has outperformed the market over the past 5 years by 7.87% on an annualized basis producing an average annual return of 17.84%. Currently, Marathon Digital Holdings has a market capitalization of $958.90 million.

Benzinga

5 Short Squeeze Candidates To Watch This Week: 2 Former SPACs Join Leaderboard With BigBear.AI Topping List

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.

Benzinga

Short Volatility Alert: Altitude Acquisition Corp

On Modnay, shares of Altitude Acquisition Corp. (NASDAQ: ALTU) experienced volatile short activity. After the activity, the stock price went up +0.10% to $9.98. The overall sentiment for ALTU has been Bullish.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Short Volatility Alert: Immunome, Inc.

On Modnay, shares of Immunome, Inc. (NASDAQ: IMNM) experienced volatile short activity. After the activity, the stock price went up +0.30% to $3.31. The overall sentiment for IMNM has been Bearish.

Benzinga

Short Volatility Alert: Catalyst Biosciences

On Modnay, shares of Catalyst Biosciences, Inc. (NASDAQ: CBIO) experienced volatile short activity. After the activity, the stock price went up +234.21% to $1.27. The overall sentiment for CBIO has been Bearish.

Benzinga

Short Volatility Alert: GeoVax Labs

On Modnay, shares of GeoVax Labs, Inc. (NASDAQ: GOVX) experienced volatile short activity. After the activity, the stock price went up +66.91% to $2.32. The overall sentiment for GOVX has been Bearish.

Benzinga

This Foreboding Sign Looms Over Expedia Group's Chart

If history is any guide, there may be trouble ahead for shares of Expedia Group (NASDAQ:EXPE). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Marine Petroleum Trust's Ex-Dividend Date Is Friday, Here's What You Need To Know

Thursday marks the last chance for investors to receive the next dividend payout from Marine Petroleum Trust (NASDAQ:MARPS).

Benzinga

EDSA: Enrollment of Phase 2b Trial of EB01 to Complete in 4Q22…

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT

Benzinga

SNGX: Phase 2a Trial of SGX302 in Psoriasis to Initiate in Second Half of 2022…

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT

Benzinga

Why Bitcoin- And Ethereum-Related Stock BitNile Is Diving Today

Bitnile Holdings Inc (NASDAQ: NILE) shares are trading lower by 12.65% at $0.27. The company reported first quarter sales results were higher year-over-year during Monday’s after-hours session.

Benzinga

Mid-Morning Market Update: Markets Open Lower; Best Buy Cuts FY23 Forecast

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Tuesday.

Benzinga

4 Analysts Have This to Say About Icon

Analysts have provided the following ratings for Icon (NASDAQ:ICLR) within the last quarter:

Benzinga

Expert Ratings for Jack In The Box

Analysts have provided the following ratings for Jack In The Box (NASDAQ:JACK) within the last quarter:

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

What 4 Analyst Ratings Have To Say About RAPT Therapeutics

Analysts have provided the following ratings for RAPT Therapeutics (NASDAQ:RAPT) within the last quarter:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022

Upgrades

Benzinga

Cannabis Movers & Shakers: Mind Medicine, 22nd Century Group, Grown Rogue International

Mind Medicine Names New CEO Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) has hired Schond L. Greenway to oversee its finance department.

Benzinga

Atlas Air Worldwide Hldgs's Return On Capital Employed Insights

Pulled from Benzinga Pro data, Atlas Air Worldwide Hldgs (NASDAQ:AAWW) posted Q1 earnings of $81.51 million, an increase from Q4 of 53.88%. Sales dropped to $1.04 billion, a 10.82% decrease between quarters.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

CommScope Holding Co's Return On Capital Employed Overview

CommScope Holding Co (NASDAQ:COMM) brought in sales totaling $2.23 billion during Q1 according to data provided by Benzinga Pro. However, earnings decreased 60.8%, resulting in a loss of $139.90 million.

Benzinga

AnaptysBio's Return On Capital Employed Insights

Benzinga Pro data, AnaptysBio (NASDAQ:ANAB) reported Q1 sales of $970.00 thousand. Earnings fell to a loss of $36.26 million, resulting in a 11.42% decrease from last quarter.

Benzinga

Looking Into European Wax Center's Return On Capital Employed

Pulled from Benzinga Pro data, European Wax Center (NASDAQ:EWCZ) showed a loss in earnings since Q4, totaling $4.03 million. Sales, on the other hand, increased by 0.7% to $45.43 million during Q1.

Benzinga

Galapagos In-licenses Inflammatory Bowel Disease Drug Targets From Scipher Medicine

Scipher Medicine announced that Galapagos (NASDAQ:GLPG) has exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD) discovered by Scipher's Spectra platform. In August 2020, Galapagos and Scipher Medicine agreed to jointly validate a suite of novel IBD targets discovered by Spectra. Galapagos has the exclusive option to in-license certain validated preclinical targets…

Benzinga

Genocea Closes Shop, Delists From NASDAQ

Genocea Biosciences Inc's (NASDAQ:GNCA) board has voted to wind down the company's ongoing operations and terminate the remaining employees except those deemed necessary to complete an orderly wind down. Yesterday, the company delivered formal notice to The Nasdaq Stock Market Inc of its intent to delist voluntarily and its plans to file a…

Benzinga

Ocugen Diversifies Its Pipeline With New Cell Therapy Platform

Ocugen Inc (NASDAQ:OCGN) says it is diversifying its pipeline by introducing a Phase 3 cell therapy platform technology called NeoCart (autologous chondrocyte-derived neocartilage). Recently, the FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to NeoCart to repair full-thickness lesions of the knee cartilage in adults. NeoCart is a three-dimensional tissue-engineered disc of…

Benzinga

Snap's Warning Has Implications For These 6 Stocks

Snap set early alarm bells ringing for social media companies with its warning concerning second-quarter performance. An analyst at KeyBanc Capital Markets sees a read-across for these six companies.

1 … 423 424 425 426

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.